PinPoint signs laboratory partnership to expand access to AI cancer risk test

Brian Attwood | November 20, 2026 | News story | |  AI, Diagnostics, NHS, Oncology, blood testing, cancer research, healthcare partnerships 

PinPoint Data Science has partnered with Alderley Lighthouse Labs to make its AI-based cancer risk blood test available through private healthcare providers and, potentially, NHS services.

Alderley Lighthouse Labs will become the first private UK laboratory to process samples for the PinPoint Test, which analyses 30 blood markers alongside a patient’s age and sex to assess cancer risk. The agreement is intended to extend access to GPs, hospitals and clinics without requiring additional laboratory equipment.

The test was developed using NHS records from 371,799 patients referred with suspected cancer and evaluated in a five-year service evaluation involving 16,481 urgent referrals across five NHS trusts and 170 GP practices.

Advertisement

The technology uses machine learning to identify patterns associated with cancer risk, with the aim of helping clinicians determine which patients require further investigation. Its initial applications cover gynaecological, upper and lower gastrointestinal, lung, and head and neck cancers.

In the NHS evaluation, the test identified 99.1% of cancers as being in an elevated or high-risk category. Among women in the lowest-risk group, its negative predictive value was 99.8%. The findings have prompted interest in using the test to support assessment of women presenting with postmenopausal bleeding, with the NHS already moving towards a pilot in this pathway.

Of around 90,000 women referred annually with postmenopausal bleeding, approximately 10% have cancer. PinPoint says its test could help identify those at lower risk and reduce unnecessary investigations, although further evaluation will be needed to establish its impact on clinical pathways.

Professor Sean Duffy, PinPoint’s chief medical officer and former NHS England national clinical director for cancer, said the technology could help clinicians distinguish patients who need urgent investigation from those at lower risk.

Cancer Research UK’s head of strategic evidence, Samantha Harrison, said further research was needed to understand the benefits for patients and the NHS, but described the evaluation findings as promising.

Pic: NCI

Related Content

NHS expands community ear and hearing pathway across 10 ICBs

A new NHS ear and hearing health pathway supported by TympaHealth has been rolled out …

PlaqueTec coronary disease trial reaches 100 patients across eight NHS centres

PlaqueTec’s BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist …

AI: an early warning system for patient safety

By Sanjeev Sachdeva Safeguarding patient health is the foremost responsibility of the pharmaceutical sector. While …

The Gateway to Local Adoption Series

Latest content